RAB22A

Summary

RAB22A (RAB22A, member RAS oncogene family, HGNC:9764) is a protein-coding gene on chromosome 20q13.32, encoding Ras-related protein Rab-22A (Q9UL26). The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes.

The protein encoded by this gene is a member of the RAB family of small GTPases. The GTP-bound form of the encoded protein has been shown to interact with early-endosomal antigen 1, and may be involved in the trafficking of and interaction between endosomal compartments.

Source: NCBI Gene 57403 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 32 total
• Druggable target: yes
• MANE Select transcript: NM_020673

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:9764
Approved symbol	RAB22A
Name	RAB22A, member RAS oncogene family
Location	20q13.32
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000124209
Ensembl biotype	protein_coding
OMIM	612966
Entrez	57403

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000244040, ENST00000488949, ENST00000870894, ENST00000870895

RefSeq mRNA: 1 — MANE Select: NM_020673 NM_020673

CCDS: CCDS33497

Canonical transcript exons

ENST00000244040 — 7 exons

Exon	Start	End
ENSE00000845802	58309715	58310012
ENSE00000845805	58353273	58353344
ENSE00000845806	58353432	58353538
ENSE00000845807	58354156	58354265
ENSE00000845808	58359606	58367507
ENSE00003541424	58343718	58343799
ENSE00003596771	58311043	58311122

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 95.63.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 26.9781 / max 242.5887, expressed in 1816 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
185495	26.9139	1816
185496	0.0642	13

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	95.63	gold quality
frontal pole	UBERON:0002795	94.94	gold quality
Brodmann (1909) area 10	UBERON:0013541	94.40	gold quality
Brodmann (1909) area 23	UBERON:0013554	94.20	gold quality
Brodmann (1909) area 46	UBERON:0006483	93.41	gold quality
middle frontal gyrus	UBERON:0002702	93.36	gold quality
oocyte	CL:0000023	93.19	gold quality
secondary oocyte	CL:0000655	92.68	gold quality
tendon of biceps brachii	UBERON:0008188	92.43	gold quality
esophagus squamous epithelium	UBERON:0006920	92.15	gold quality
orbitofrontal cortex	UBERON:0004167	91.87	gold quality
postcentral gyrus	UBERON:0002581	91.46	gold quality
adrenal tissue	UBERON:0018303	91.38	gold quality
visceral pleura	UBERON:0002401	91.26	gold quality
parietal pleura	UBERON:0002400	91.24	gold quality
pleura	UBERON:0000977	91.14	gold quality
periodontal ligament	UBERON:0008266	91.12	gold quality
tongue squamous epithelium	UBERON:0006919	90.96	gold quality
gingival epithelium	UBERON:0001949	90.86	gold quality
parietal lobe	UBERON:0001872	90.82	gold quality
gingiva	UBERON:0001828	90.81	gold quality
endometrium epithelium	UBERON:0004811	90.56	gold quality
superior frontal gyrus	UBERON:0002661	90.55	gold quality
epithelium of esophagus	UBERON:0001976	90.44	gold quality
pons	UBERON:0000988	90.22	gold quality
skin of hip	UBERON:0001554	89.95	gold quality
cerebellar vermis	UBERON:0004720	89.87	gold quality
squamous epithelium	UBERON:0006914	89.87	gold quality
paraflocculus	UBERON:0005351	89.78	gold quality
germinal epithelium of ovary	UBERON:0001304	89.52	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.58

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

303 targeting RAB22A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-9-5P	100.00	72.28	2361
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-4425	100.00	67.59	1049
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-4775	99.98	75.00	6394

Literature-anchored findings (GeneRIF, showing 37)

• Rab22a may regulate the dynamic interactions of endosomal compartments and it may be involved in the communication between the biosynthetic and early endocytic pathways. (PMID:11870209)
• Rab22a regulates different steps in the recycling of cargo protein that has entered the cell independently of clathrin. (PMID:15181155)
• Rab22a can affect the trafficking from endosomes to the Golgi apparatus probably by promoting fusion among endosomes and impairing the proper segregation of membrane domains required for targeting to the trans-Golgi network (TGN). (PMID:15748882)
• Rab22a controls the transport of the transferrin receptor from sorting to recycling endosomes. (PMID:16537905)
• Data report the identification of Rab22 as a binding site on early endosomes for direct recruitment of Rabex-5 and activation of Rab5, establishing a Rab22-Rab5 signaling relay to promote early endosome fusion. (PMID:19759177)
• Exposure of human breast cancer cells to hypoxia augments microvesicle (MVs) shedding that is mediated by the HIF-dependent expression of the small GTPase RAB22A, which colocalizes with budding MVs at the cell surface. (PMID:24938788)
• miR-204-5p acts as a tumor suppressor in colorectal cancer through inhibiting RAB22A and reveal RAB22A to be a new oncogene and prognostic factor for colorectal cancer. (PMID:25294901)
• miR-204-5p acts as a tumor suppressor in gastric cancer through inhibiting USP47 and RAB22A. (PMID:25429829)
• these results demonstrate that miR-373 suppresses epithelial ovarian cancer invasion and metastasis by directly targeting Rab22a gene (PMID:25460499)
• Re-expression of miR-193b in breast cancer cell lines decreased DNAJC13 (HPS40) and RAB22A expression, providing a mechanism by which mir193-b acts as a tumor suppressor. (PMID:25550792)
• Vaccinia virus traffics to early endosomes, where recycling endosome markers Rab11 and Rab22 are recruited to participate in subsequent virus trafficking prior to virus core uncoating in the cytoplasm. (PMID:26041286)
• Data show that Rab22a- and Rab5a-driven phagosomal uptake is a crucial step in the vesicular cascade that leads to elimination of spirochetes by macrophages. (PMID:26344766)
• miR-204 suppressed renal cell carcinoma proliferation and invasion by directly targeting the RAB22A gene. (PMID:26883716)
• RAB22A role in epithelial-mesenchymal transition of melanoma cells (PMID:27237979)
• Rab3A-22A blocks exocytosis at a stage downstream intra-acrosomal calcium release. (PMID:27613869)
• that Rab22a enhances recycling of CD147, which is required for lung cancer cell migration and invasion (PMID:28433697)
• Differential requirement of Rab22a for the recruitment of ER-derived proteins to phagosomes and endosomes in dendritic cells. (PMID:28960134)
• Study shows that the upregulation of RAB22A is associated with breast cancer progression and lymph node metastasis. Findings demonstrate that oncogenic RAB22A, regulated by miR-193b, affects the exosome-mediated growth, invasion, and metastasis of the recipient breast cancer cells. (PMID:30272274)
• Rab22A promotes the assembly of a BLOC-1-BLOC-2-KIF13A complex on early/sorting endosomes. (PMID:30404817)
• Overexpressing miR373 mimics in liver cancer cell lines decreased cell proliferation and invasion, suggesting that miR373 exerts antitumor effects in liver cancer. In addition, data from the present study demonstrated the direct effect of miR373 on inhibiting the expression and signaling of Rasrelated protein Rab22a, a wellknown oncoprotein. (PMID:31485646)
• LncRNA DLEU1/microRNA-300/RAB22A axis regulates migration and invasion of breast cancer cells. (PMID:31841195)
• Rab22a is a novel prognostic marker for cell progression in breast cancer. (PMID:32124943)
• Chromosomal translocation-derived aberrant Rab22a drives metastasis of osteosarcoma. (PMID:32483387)
• Acetylation dependent functions of Rab22a-NeoF1 Fusion Protein in Osteosarcoma. (PMID:32685017)
• Rab22a-NeoF1: a promising target for osteosarcoma patients with lung metastasis. (PMID:32839478)
• Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes. (PMID:33568623)
• LncRNA MIAT Mediates ox-LDL-Induced Endothelial Cell Injury Via miR-206/RAB22A Axis. (PMID:33965771)
• Rab22a promotes the proliferation, migration, and invasion of lung adenocarcinoma via up-regulating PI3K/Akt/mTOR signaling pathway. (PMID:35487271)
• Rab22a Promotes Epithelial-Mesenchymal Transition in Papillary Thyroid Carcinoma by Activating PI3K/AKT/mTOR Signaling Pathway. (PMID:35757470)
• A novel membrane targeting domain mediates the endosomal or Golgi localization specificity of small GTPases Rab22 and Rab31. (PMID:35863437)
• Circular RNA circ_0029589 promotes ox-LDL-induced endothelial cell injury through regulating RAB22A by serving as a sponge of miR-1197. (PMID:36683504)
• miR-204 suppresses uveal melanoma cell migration and invasion through negative regulation of RAB22A. (PMID:36705739)
• Vps9d1 regulates tubular endosome formation through specific activation of Rab22A. (PMID:36762583)
• Circ-C16orf62 Regulates Oxidized low-density Lipoprotein-induced Apoptosis, Inflammation, Oxidative Stress and Cholesterol Accumulation of Macrophages via Mediating RAB22A Expression by Targeting miR-377. (PMID:36892682)
• RAB22A as a predictor of exosome secretion in the progression and relapse of multiple myeloma. (PMID:38431306)
• The ras-related protein RAB22A interacts with hypoxia-inducible factor 1-alpha (HIF-1alpha) in MDA-MB-231 breast cancer cells in hypoxia. (PMID:38647725)
• Genomic Amplification of TBC1D31 Promotes Hepatocellular Carcinoma Through Reducing the Rab22A-Mediated Endolysosomal Trafficking and Degradation of EGFR. (PMID:39206796)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	rab22a	ENSDARG00000015807
mus_musculus	Rab22a	ENSMUSG00000027519
rattus_norvegicus	Rab22a	ENSRNOG00000005762

Paralogs (68): RAB27B (ENSG00000041353), RAB27A (ENSG00000069974), RAB7A (ENSG00000075785), RABL2B (ENSG00000079974), RAB21 (ENSG00000080371), RAB10 (ENSG00000084733), RAB18 (ENSG00000099246), RAB36 (ENSG00000100228), IFT27 (ENSG00000100360), RAB40AL (ENSG00000102128), RAB11A (ENSG00000103769), RAB2A (ENSG00000104388), RAB3D (ENSG00000105514), RAB3A (ENSG00000105649), RAB5C (ENSG00000108774), RAB34 (ENSG00000109113), RAB5B (ENSG00000111540), RAB35 (ENSG00000111737), RAB23 (ENSG00000112210), DNAJC27 (ENSG00000115137), RAB29 (ENSG00000117280), RAB32 (ENSG00000118508), RAB14 (ENSG00000119396), RAB9B (ENSG00000123570), RAB9A (ENSG00000123595), RAB38 (ENSG00000123892), RAB17 (ENSG00000124839), RAB2B (ENSG00000129472), RAB25 (ENSG00000132698), RAB33A (ENSG00000134594), RAB30 (ENSG00000137502), RAB1A (ENSG00000138069), RAB20 (ENSG00000139832), RAB15 (ENSG00000139998), RAB40B (ENSG00000141542), RAB13 (ENSG00000143545), RABL2A (ENSG00000144134), RAB5A (ENSG00000144566), RAB19 (ENSG00000146955), RAB41 (ENSG00000147127)

Protein

Protein identifiers

Ras-related protein Rab-22A — Q9UL26 (reviewed: Q9UL26)

All UniProt accessions (1): Q9UL26

UniProt curated annotations — full annotation on UniProt →

Function. The small GTPases Rab are key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive GDP-bound form and an active GTP-bound form that is able to recruit to membranes different sets of downstream effectors directly responsible for vesicle formation, movement, tethering and fusion. RAB22A plays a role in endocytosis and intracellular protein transport. Mediates trafficking of transferrin/TF from early endosomes to recycling endosomes. Required for NGF-mediated endocytosis of NTRK1, and subsequent neurite outgrowth. Has low GTPase activity.

Subunit / interactions. Interacts directly with ZFYVE20. Binds EEA1. Interacts (in its GTP-bound form) with RABGEF1. Interacts (in its GTP-bound form) with RINL.

Subcellular location. Endosome membrane. Cell membrane. Early endosome. Late endosome. Cell projection. Ruffle. Cytoplasmic vesicle. Phagosome. Phagosome membrane.

Activity regulation. Regulated by guanine nucleotide exchange factors (GEFs) including RINL, which promote the exchange of bound GDP for free GTP. Regulated by GTPase activating proteins (GAPs) which increase the GTP hydrolysis activity. Inhibited by GDP dissociation inhibitors (GDIs).

Domain organisation. Switch I, switch II and the interswitch regions are characteristic of Rab GTPases and mediate the interactions with Rab downstream effectors. The switch regions undergo conformational changes upon nucleotide binding which drive interaction with specific sets of effector proteins, with most effectors only binding to GTP-bound Rab.

Similarity. Belongs to the small GTPase superfamily. Rab family.

RefSeq proteins (1): NP_065724* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001806	Small_GTPase	Family
IPR005225	Small_GTP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF00071

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (28 total): binding site 17, region of interest 3, lipid moiety-binding region 2, mutagenesis site 2, sequence conflict 2, chain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UL26-F1	89.79	0.80

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (17): 19; 20; 31; 32; 37; 37; 63; 118; 119; 121; 149; 150 …

Post-translational modifications (2): 193, 194

Mutagenesis-validated functional residues (2):

Position	Phenotype
19	loss of gtpase activity.
64	constitutive gtpase activity. impairs normal protein trafficking through early endosomes.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8873719	RAB geranylgeranylation

MSigDB gene sets: 236 (showing top): RNGTGGGC_UNKNOWN, GCM_MAP4K4, GOBP_ENDOSOME_ORGANIZATION, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_VESICLE_ORGANIZATION, DITTMER_PTHLH_TARGETS_UP, TGACCTY_ERR1_Q2, GOBP_VESICLE_MEDIATED_TRANSPORT, GOCC_RUFFLE, LHX3_01, YY1_Q6, GTGCCTT_MIR506, AMIT_EGF_RESPONSE_480_MCF10A, GOBP_REGULATION_OF_ANATOMICAL_STRUCTURE_SIZE, GGGCATT_MIR365

GO Biological Process (5): intracellular protein transport (GO:0006886), endocytosis (GO:0006897), endosome organization (GO:0007032), regulation of vesicle size (GO:0097494), protein transport (GO:0015031)

GO Molecular Function (6): GTPase activity (GO:0003924), G protein activity (GO:0003925), GTP binding (GO:0005525), GDP binding (GO:0019003), nucleotide binding (GO:0000166), protein binding (GO:0005515)

GO Cellular Component (15): ruffle (GO:0001726), early endosome (GO:0005769), late endosome (GO:0005770), Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), endosome membrane (GO:0010008), endomembrane system (GO:0012505), actin cytoskeleton (GO:0015629), phagocytic vesicle membrane (GO:0030670), phagocytic vesicle (GO:0045335), extracellular exosome (GO:0070062), endosome (GO:0005768), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
endosome	3
cellular anatomical structure	3
intracellular protein localization	2
guanyl ribonucleotide binding	2
cytoplasm	2
endomembrane system	2
protein transport	1
intracellular transport	1
vesicle budding from membrane	1
membrane invagination	1
vesicle-mediated transport	1
import into cell	1
endomembrane system organization	1
vesicle organization	1
regulation of cellular component size	1
transport	1
establishment of protein localization	1
ribonucleoside triphosphate phosphatase activity	1
GTPase activity	1
molecular function regulator activity	1
purine ribonucleoside triphosphate binding	1
anion binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
cell leading edge	1
plasma membrane bounded cell projection	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
vacuole	1
plasma membrane	1
cytoskeleton	1
endocytic vesicle membrane	1
phagocytic vesicle	1
endocytic vesicle	1
extracellular vesicle	1
cytoplasmic vesicle	1

Protein interactions and networks

STRING

1346 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RAB22A	RABGEF1	Q9UJ41	880
RAB22A	RAD51AP1	Q96B01	845
RAB22A	TBC1D10B	Q4KMP7	823
RAB22A	TBC1D10A	Q9BXI6	779
RAB22A	RABEP1	Q15276	759
RAB22A	RBSN	Q9H1K0	719
RAB22A	EEA1	Q15075	711
RAB22A	AGA	P20933	662
RAB22A	EIF3K	Q9UBQ5	634
RAB22A	CLTC	Q00610	576
RAB22A	CDC16	Q13042	576
RAB22A	USP6	P35125	568
RAB22A	TFRC	P02786	567
RAB22A	TBC1D2B	Q9UPU7	562
RAB22A	ARRDC1	Q8N5I2	546

IntAct

34 interactions, top by confidence:

A	B	Type	Score
APPL2	RAB22A	psi-mi:“MI:0915”(physical association)	0.830
RAB22A	APPL2	psi-mi:“MI:0915”(physical association)	0.830
GDI1	RAB4A	psi-mi:“MI:0914”(association)	0.820
EEA1	RAB22A	psi-mi:“MI:0915”(physical association)	0.650
RAB22A	EEA1	psi-mi:“MI:0915”(physical association)	0.650
RAB31	CHM	psi-mi:“MI:0914”(association)	0.640
ALS2CL	RAB22A	psi-mi:“MI:0915”(physical association)	0.560
vipD	RAB22A	psi-mi:“MI:0407”(direct interaction)	0.440
RAB22A	APPL1	psi-mi:“MI:0407”(direct interaction)	0.440
RBSN	RAB22A	psi-mi:“MI:0915”(physical association)	0.400
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
ATP6V1A		psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350
Npc1	ESYT2	psi-mi:“MI:0914”(association)	0.350
GDI1	U2SURP	psi-mi:“MI:0914”(association)	0.350
GDI2	SGTA	psi-mi:“MI:0914”(association)	0.350
GDI1	NADK	psi-mi:“MI:0914”(association)	0.350
FECH	POTEF	psi-mi:“MI:0914”(association)	0.350
MYC	AP3B1	psi-mi:“MI:0914”(association)	0.350
GATA2	EFCAB5	psi-mi:“MI:0914”(association)	0.350
RAB22A	APPL2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (38): RAB22A (Two-hybrid), RAB22A (Affinity Capture-MS), RAB22A (Two-hybrid), RAB22A (Affinity Capture-MS), RAB22A (Affinity Capture-MS), APPL2 (Two-hybrid), ALS2CL (Two-hybrid), RAB22A (Two-hybrid), RAB22A (Proximity Label-MS), RAB22A (Proximity Label-MS), RAB22A (Proximity Label-MS), RAB22A (Proximity Label-MS), RAB22A (Affinity Capture-MS), EEA1 (Reconstituted Complex), RAB22A (Affinity Capture-MS)

ESM2 similar proteins: A6QR46, C4YL11, O18334, O23657, O80501, P0CY30, P0CY31, P10949, P17608, P20340, P20790, P20791, P34140, P34141, P34142, P34143, P34213, P35279, P35293, P35294, P36017, P36019, P61294, P90726, Q05976, Q0IIG8, Q1KME6, Q22782, Q28IZ3, Q54DA7, Q54GY8, Q54NU2, Q55ET3, Q55FK2, Q58DS5, Q5EB77, Q5KTJ6, Q5R5H5, Q5RAV6, Q5ZLG1

Diamond homologs: A6QR46, M0RC99, O01803, O04486, O18334, O35509, P10536, P16976, P17608, P17610, P18066, P20339, P20340, P22125, P22129, P25766, P28185, P28188, P29687, P31582, P31583, P31584, P34140, P34213, P35278, P35279, P35282, P35285, P35292, P36017, P36018, P36019, P36586, P38555, P40392, P46638, P51147, P51148, P51154, P55745

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
RAB22A	“form complex”	“Early Endosome”	binding
RAB22A	“up-regulates activity”	BLOC-2	relocalization

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 26 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RAB GEFs exchange GTP for GDP on RABs	5	28.2×	1e-04

GO biological processes:

GO term	Partners	Fold	FDR
vesicle-mediated transport	5	20.9×	4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

32 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	20
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1191 predictions. Top by Δscore:

Variant	Effect	Δscore
20:58311040:CAG:C	acceptor_loss	1.0000
20:58311041:A:C	acceptor_loss	1.0000
20:58311041:AG:A	acceptor_gain	1.0000
20:58311042:GG:G	acceptor_gain	1.0000
20:58311120:AGGG:A	donor_loss	1.0000
20:58311121:GG:G	donor_gain	1.0000
20:58311122:GG:G	donor_gain	1.0000
20:58311122:GGTAA:G	donor_loss	1.0000
20:58311123:G:C	donor_loss	1.0000
20:58311123:G:GG	donor_gain	1.0000
20:58311124:T:A	donor_loss	1.0000
20:58343800:G:GG	donor_gain	1.0000
20:58353342:G:GT	donor_gain	1.0000
20:58353342:GAA:G	donor_gain	1.0000
20:58353345:G:GG	donor_gain	1.0000
20:58353424:T:TA	acceptor_gain	1.0000
20:58353430:A:AG	acceptor_gain	1.0000
20:58353430:A:C	acceptor_loss	1.0000
20:58353430:AG:A	acceptor_gain	1.0000
20:58353431:G:GG	acceptor_gain	1.0000
20:58353431:GG:G	acceptor_gain	1.0000
20:58353431:GGA:G	acceptor_gain	1.0000
20:58353431:GGAGA:G	acceptor_gain	1.0000
20:58353534:GTAAG:G	donor_gain	1.0000
20:58353539:G:GA	donor_loss	1.0000
20:58353539:G:GG	donor_gain	1.0000
20:58354261:AATTA:A	donor_gain	1.0000
20:58354263:TTA:T	donor_gain	1.0000
20:58354266:G:GG	donor_gain	1.0000
20:58359601:TTTA:T	acceptor_loss	1.0000

AlphaMissense

1272 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:58343776:T:A	W59R	1.000
20:58343776:T:C	W59R	1.000
20:58343779:G:C	D60H	1.000
20:58343780:A:C	D60A	1.000
20:58343780:A:G	D60G	1.000
20:58343780:A:T	D60V	1.000
20:58353273:T:C	F67L	1.000
20:58353275:T:A	F67L	1.000
20:58353275:T:G	F67L	1.000
20:58353517:A:T	K119I	1.000
20:58310010:G:A	G12R	0.999
20:58310010:G:C	G12R	0.999
20:58310010:G:T	G12W	0.999
20:58310011:G:A	G12E	0.999
20:58311055:G:C	G17R	0.999
20:58311056:G:A	G17D	0.999
20:58311056:G:T	G17V	0.999
20:58311058:A:C	K18Q	0.999
20:58311059:A:T	K18I	0.999
20:58311060:A:C	K18N	0.999
20:58311060:A:T	K18N	0.999
20:58311061:T:C	S19P	0.999
20:58311062:C:T	S19L	0.999
20:58311077:G:C	R24P	0.999
20:58311094:T:C	F30L	0.999
20:58311096:T:A	F30L	0.999
20:58311096:T:G	F30L	0.999
20:58311121:G:A	G39R	0.999
20:58311121:G:C	G39R	0.999
20:58311122:G:A	G39E	0.999

dbSNP variants (sampled 300 via entrez): RS1000107430 (20:58323175 T>C), RS1000184862 (20:58355716 C>G,T), RS1000228774 (20:58335177 A>G), RS1000387809 (20:58341644 T>C), RS1000394666 (20:58342023 AAATAAT>A,AAAT,AAATAATAAT,AAATAATAATAAT), RS1000462218 (20:58335867 A>G), RS1000550818 (20:58327944 G>A,C), RS1000590600 (20:58346996 T>C), RS1000695658 (20:58340295 G>C), RS1000718655 (20:58340126 C>T), RS1000725047 (20:58340516 G>A,C), RS1000826255 (20:58335484 G>A), RS1000861942 (20:58322736 T>C), RS1000871464 (20:58316580 T>C), RS1000955810 (20:58352755 A>C)

Disease associations

OMIM: gene MIM:612966 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST002928_26	Nickel levels	7.000000e-06
GCST004790_4	Change in LVEF in response to paclitaxel and trastuzumab in HER2+ breast cancer	6.000000e-06
GCST009391_1396	Metabolite levels	1.000000e-06
GCST012244_8	Childhood asthma exacerbations in long-acting beta2-agonist treatment	9.000000e-07
GCST90000025_692	Appendicular lean mass	1.000000e-14

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0008204	left ventricular diastolic function measurement
EFO:0008347	response to trastuzumab
EFO:0010369	lysophosphatidylethanolamine 18:2 measurement
EFO:0007614	asthma exacerbation measurement
EFO:0004980	appendicular lean mass

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295981 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, increases expression, increases methylation, affects expression	5
sodium arsenite	increases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Cyclosporine	increases expression	2
Cadmium Chloride	increases expression	2
aristolochic acid I	increases expression	1
FR900359	decreases phosphorylation	1
methylmercuric chloride	decreases expression	1
2-butenal	decreases expression	1
hydroxyhydroquinone	increases expression	1
cobaltous chloride	increases expression	1
butyraldehyde	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
ICG 001	increases expression	1
PCI 5002	increases expression, affects cotreatment	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	decreases expression	1
Sunitinib	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Atrazine	decreases expression	1
Benzene	increases expression	1
Benzo(a)pyrene	affects methylation	1
Carbamazepine	affects expression	1
Doxorubicin	decreases expression	1
Formaldehyde	increases expression	1
Nickel	increases expression	1
Ozone	affects expression, increases abundance	1
Testosterone	decreases expression	1
Thiram	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118948	Binding	Binding affinity to RAB22A in human NCI-H358 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Cellosaurus cell lines

17 cell lines: 17 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_0179	BT-474	Cancer cell line	Female
CVCL_4V65	BT474-5FU[r]	Cancer cell line	Female
CVCL_4Y08	BT-474/CMV-Luc	Cancer cell line	Female
CVCL_A2GH	LR-BT474	Cancer cell line	Female
CVCL_A4AK	BT-474 Tam2	Cancer cell line	Female
CVCL_A4CL	BT-474 Ecadherin EmGFP	Cancer cell line	Female
CVCL_A7AJ	HeLa M Rab22-DKO	Cancer cell line	Female
CVCL_AQ07	BT-474 Clone 5	Cancer cell line	Female
CVCL_AR86	BT-474 Tam1	Cancer cell line	Female
CVCL_AR96	BT-474 EEI	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.